前立腺肥大症に伴う排尿障害に対する臭化ジスチグミン(ウブレチド)の臨床評価 : αブロッカー併用投与との比較試験

Abstract

保存的治療が可能と判断された前立腺肥大症20例に臭化ジスチグミン単独投与, 塩酸プラゾシン併用投与をおこない8週目に自, 他覚症状の改善度を比較検討した.1)総合改善度は併用投与群で9例中9例, 単独群では11例中8例に認められたが, 両群間に有意差はなかった.2)自覚症状として排尿困難の改善や, 排尿回数の減少が両群共に有意に観察された.3)他覚的所見としては, 残尿率の有意の改善が両群で認められ, 最大尿流量率, 平均尿流量率は併用投与群で有意な上昇がえられた

We report the results of a comparative study on the clinical efficacy of the single use of distigmine bromide and its combined use with prazosin hydrochloride in the treatment of benign prostatic hypertrophy. The single use and combined use groups were administered 10 mg/day of distigmine bromide and the same with 1 mg/day of prazosin hydrochloride for a period of 8 weeks respectively. In the single administration group, marked improvement was found in one patient (9%), moderate improvement in 4 patients (36.3%), slight improvement in 3 patients (27.2%) and aggravation in 3 patients. In the combined use group, marked improvement was found in one patient (11.0%), moderate improvement in 5 patients (55.5%), and slight improvement in 3 patients (33.3%). No significant differences were found in the improvement rate between the two groups. However, significant improvements were found in both groups for the subjective symptoms of urinary disturbance, diurnal and nocturnal frequency. As a result of the examination of objective findings, a significant decrease in residual urine ratio was also shown in both groups, while significant improvement for average flow and maximum flow rates were found in only the combined use group. In conclusion, distigmine bromide and distigmine bromide+prazosin hydrochloride are considered very useful for the treatment of miturition disturbance due to benign prostatic hypertrophy.